Monte Rosa Therapeutics (GLUE) Net Cash Flow (QoQ) (2020 - 2026)
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Net Cash Flow (QoQ) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Monte Rosa Therapeutics | 1.41 Bn | 781.72 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -332.78% |
| Mar 31, 2026 | 138.20% |
| Dec 31, 2025 | -156.48% |
| Sep 30, 2025 | 1,638.19% |
| Jun 30, 2025 | 93.80% |
| Mar 31, 2025 | -247.72% |
| Dec 31, 2024 | 488.16% |
| Sep 30, 2024 | 84.33% |
| Jun 30, 2024 | 132.42% |
| Mar 31, 2024 | -140.61% |
| Dec 31, 2023 | 474.77% |
| Sep 30, 2023 | 315.70% |
| Jun 30, 2023 | -82.04% |
| Mar 31, 2023 | 94.67% |
| Dec 31, 2022 | -762.66% |
| Sep 30, 2022 | 125.02% |
| Jun 30, 2022 | 83.32% |
| Mar 31, 2022 | -1,097.25% |
| Dec 31, 2021 | -273.99% |
| Sep 30, 2021 | -94.73% |